These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 33509909)

  • 1. Initial triple therapy in pulmonary arterial hypertension: coming of age and rejuvenated.
    Bogaard HJ; Sitbon O
    Eur Respir J; 2021 Jan; 57(1):. PubMed ID: 33509909
    [No Abstract]   [Full Text] [Related]  

  • 2. Initial Triple Combination Therapy for Intermediate-and High-Risk Pulmonary Arterial Hypertension: Standard of Care or Still Too Soon to Tell?
    Jin Q; Guan L; Pan W; Zhou D
    Am J Respir Crit Care Med; 2021 Dec; 204(12):1491-1492. PubMed ID: 34672865
    [No Abstract]   [Full Text] [Related]  

  • 3. Counterpoint: Should the Use of Upfront Triple Combination Therapy Be Standard of Care in Pulmonary Arterial Hypertension? No.
    Sahay S
    Chest; 2024 Mar; 165(3):494-496. PubMed ID: 38461012
    [No Abstract]   [Full Text] [Related]  

  • 4. POINT: Should the Use of Upfront Triple Combination Therapy Be Standard of Care in Pulmonary Arterial Hypertension? Yes.
    Weatherald J; Sitbon O
    Chest; 2024 Mar; 165(3):492-494. PubMed ID: 38461011
    [No Abstract]   [Full Text] [Related]  

  • 5. Surrogate endpoints in pulmonary arterial hypertension trials.
    Hoeper MM
    Lancet Respir Med; 2023 Oct; 11(10):852-853. PubMed ID: 37230096
    [No Abstract]   [Full Text] [Related]  

  • 6. Pulmonary Hypertension Associated With Respiratory Diseases　- Which Patients Should Be Treated With Pulmonary Arterial Hypertension-Targeted Therapies?
    Sakamaki F; Asano K
    Circ J; 2021 Mar; 85(4):343-344. PubMed ID: 33563867
    [No Abstract]   [Full Text] [Related]  

  • 7. Continued Progress in Therapy for Pulmonary Arterial Hypertension.
    Taichman DB; Leopold JA; Elliott G
    N Engl J Med; 2023 Apr; 388(16):1524-1526. PubMed ID: 36876747
    [No Abstract]   [Full Text] [Related]  

  • 8. COUNTERPOINT: Should Initial Combination Therapy Be the Standard of Care in Pulmonary Arterial Hypertension? No.
    Channick RN; Saggar R
    Chest; 2019 Dec; 156(6):1043-1045. PubMed ID: 31812189
    [No Abstract]   [Full Text] [Related]  

  • 9. Upfront Combination Therapy: Growing the Case to Get Ahead of Pediatric Pulmonary Arterial Hypertension.
    Steffes LC; Austin ED
    Ann Am Thorac Soc; 2022 Feb; 19(2):163-165. PubMed ID: 35103566
    [No Abstract]   [Full Text] [Related]  

  • 10. Viewpoint: activin signalling inhibitors for the treatment of pulmonary arterial hypertension.
    Humbert M
    Eur Respir J; 2023 Nov; 62(5):. PubMed ID: 37918877
    [No Abstract]   [Full Text] [Related]  

  • 11. Update on pediatric pulmonary arterial hypertension.
    Ivy D; Frank BS
    Curr Opin Cardiol; 2021 Jan; 36(1):67-79. PubMed ID: 33136663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Win Statistics in Pulmonary Arterial Hypertension Clinical Trials.
    Weatherald J; Moutchia J; Al-Naamani N; McClelland RL; Ventetuolo CE; Palevsky HI; Harhay MO; Kawut SM
    Am J Respir Crit Care Med; 2023 Dec; 208(11):1231-1234. PubMed ID: 37734029
    [No Abstract]   [Full Text] [Related]  

  • 13. Prostaglandin I
    Norlander AE; Abney M; Cephus JY; Roe CE; Irish JM; Shelburne NJ; Newcomb DC; Hemnes AR; Peebles RS
    Am J Respir Crit Care Med; 2023 Sep; 208(6):737-739. PubMed ID: 37413696
    [No Abstract]   [Full Text] [Related]  

  • 14. Initial Triple Pharmacotherapy in Pulmonary Arterial Hypertension: Is More Necessarily Better?
    Leopold JA
    J Am Coll Cardiol; 2021 Oct; 78(14):1404-1406. PubMed ID: 34593121
    [No Abstract]   [Full Text] [Related]  

  • 15. Results of atrial flow regulator implantation in pulmonary arterial hypertension patients with severe heart failure despite maximal medical therapy.
    Kopeć G; Araszkiewicz A; Magoń W; Stępniewski J; Sławek-Szmyt S; Janus M; Skoczylas I; Gąsior Z; Wilczek Ł; Komar M; Gackowski A; Sabiniewicz A
    Kardiol Pol; 2024; 82(1):75-78. PubMed ID: 37537913
    [No Abstract]   [Full Text] [Related]  

  • 16. Multilevel omics: A next step on the way to understanding pulmonary arterial hypertension?
    Aman J; Hovingh GK
    Thorax; 2019 Apr; 74(4):317-318. PubMed ID: 30679265
    [No Abstract]   [Full Text] [Related]  

  • 17. Deconstructing the Melting Pot in Pulmonary Arterial Hypertension.
    Austin ED; Hamid R
    Am J Respir Crit Care Med; 2020 Jun; 201(11):1329-1331. PubMed ID: 32053755
    [No Abstract]   [Full Text] [Related]  

  • 18. Adding an important piece to the pulmonary vascular resistance puzzle in pulmonary arterial hypertension.
    Maron BA; Humbert M
    Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32646896
    [No Abstract]   [Full Text] [Related]  

  • 19. Checkpoint Kinase 1 Promotes the Development of Pulmonary Arterial Hypertension.
    Satoh K; Kikuchi N; Kurosawa R; Shimokawa H
    Arterioscler Thromb Vasc Biol; 2019 Aug; 39(8):1504-1506. PubMed ID: 31339778
    [No Abstract]   [Full Text] [Related]  

  • 20. "Rehab for all!" Is it too early in pulmonary arterial hypertension?
    Bertoletti L; Bouvaist H; Tromeur C; Bezzeghoud S; Dauphin C; Enache I; Bourdin A; Seronde MF; Montani D; Turquier S; Pison C; ;
    Eur Respir J; 2019 Nov; 54(5):. PubMed ID: 31699779
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.